Progesterone (P4) is a medication and naturally occurring steroid hormone. It is a progestogen and is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels in women. It is also used in women to support pregnancy and fertility and to treat gynecological disorders. Progesterone can be taken by mouth, in through the vagina, and by injection into muscle or fat, among other routes. A progesterone vaginal ring and progesterone intrauterine device used for birth control also exist in some areas of the world.
Progesterone is well-tolerated and often produces few or no side effects. However, a number of side effects are possible, for instance mood changes. If progesterone is taken by mouth or at high doses, certain central side effects including sedation, sleepiness, and cognitive impairment can also occur. The medication is a naturally occurring progestogen and hence is an agonist of the progesterone receptor (PR), the biological target of progestogens like endogenous progesterone. It opposes the effects of estrogens in various parts of the body like the uterus and also blocks the effects of the hormone aldosterone. In addition, progesterone has neurosteroid effects in the brain.
Progesterone was first isolated in pure form in 1934. It first became available as a medication later that year. Oral micronized progesterone (OMP), which allowed progesterone to be taken by mouth, was introduced in 1980. A large number of synthetic progestogens, or progestins, have been derived from progesterone and are used as medications as well. Examples include medroxyprogesterone acetate and norethisterone. In 2016 it was the 189th most prescribed medication in the United States with more than 3 million prescriptions.
- 1 Medical uses
- 2 Contraindications
- 3 Side effects
- 4 Overdose
- 5 Interactions
- 6 Pharmacology
- 7 Chemistry
- 8 History
- 9 Society and culture
- 10 See also
- 11 References
- 12 Further reading
Progesterone is used in combination with an estrogen as a component of menopausal hormone therapy for the treatment of menopausal symptoms. A progestogen is needed to prevent endometrial hyperplasia and increased risk of endometrial cancer caused by unopposed estrogens in women who have intact uteruses. In addition, progestogens, including progesterone, are able to treat and improve hot flashes. Progesterone, both alone and in combination with an estrogen, also has beneficial effects on skin health and is able to slow the rate of skin aging in postmenopausal women.
Based on animal research, progesterone may be involved in sexual function in women. However, very limited clinical research suggests that progesterone does not improve sexual desire or function in women.
Progesterone is used as a component of feminizing hormone therapy for transgender women in combination with estrogens and antiandrogens. However, the addition of progestogens to HRT for transgender women is controversial and their role is unclear. Some patients and clinicians believe anecdotally that progesterone may enhance breast development, improve mood, and increase sex drive. However, there is a lack of evidence from well-designed studies to support these notions at present. In addition, progestogens can produce undesirable side effects, although bioidentical progesterone may be safer and better tolerated than synthetic progestogens like medroxyprogesterone acetate.
Because some believe that progestogens are necessary for full breast development, progesterone is sometimes used in transgender women with the intention of enhancing breast development. However, a 2014 review concluded the following on the topic of progesterone for enhancing breast development in transgender women:
- "Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in [transgender] women is extremely sparse and based on low quality of evidence. Current evidence does not provide evidence that progestogens enhance breast development in [transgender] women. Neither do they prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions."
While the influence of progesterone on breast development is uncertain, it is known that progesterone can cause temporary breast enlargement due to local fluid retention in the breasts, and this may give a misleading appearance of breast growth. Aside from a hypothetical involvement in breast development, progestogens are not otherwise known to be involved in physical feminization.
Vaginally dosed progesterone is being investigated as potentially beneficial in preventing preterm birth in women at risk for preterm birth. The initial study by Fonseca suggested that vaginal progesterone could prevent preterm birth in women with a history of preterm birth. According to a recent study, women with a short cervix that received hormonal treatment with a progesterone gel had their risk of prematurely giving birth reduced. The hormone treatment was administered vaginally every day during the second half of a pregnancy. A subsequent and larger study showed that vaginal progesterone was no better than placebo in preventing recurrent preterm birth in women with a history of a previous preterm birth, but a planned secondary analysis of the data in this trial showed that women with a short cervix at baseline in the trial had benefit in two ways: a reduction in births less than 32 weeks and a reduction in both the frequency and the time their babies were in intensive care.
In another trial, vaginal progesterone was shown to be better than placebo in reducing preterm birth prior to 34 weeks in women with an extremely short cervix at baseline. An editorial by Roberto Romero discusses the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. A meta-analysis published in 2011 found that vaginal progesterone cut the risk of premature births by 42 percent in women with short cervixes. The meta-analysis, which pooled published results of five large clinical trials, also found that the treatment cut the rate of breathing problems and reduced the need for placing a baby on a ventilator.
Progesterone is used for luteal support in assisted reproductive technology (ART) cycles such as in vitro fertilization (IVF). It is also used to correct luteal phase deficiency to prepare the endometrium for implantation in infertility therapy and is used to support early pregnancy.
A progesterone vaginal ring is available for birth control when breastfeeding in a number of areas of the world. An intrauterine device containing progesterone has also been marketed under the brand name Progestasert for birth control, including previously in the United States.
Progesterone is used to control persistent anovulatory bleeding. It is used in non-pregnant women with a delayed menstruation of one or more weeks, in order to allow the thickened endometrial lining to slough off. This process is termed a progesterone withdrawal bleed. Progesterone is taken orally for a short time (usually one week), after which it is discontinued and bleeding should occur.
Progesterone is approved under the brand name Progestogel as a 1% topical gel for local application to the breasts to treat breast pain in certain countries. It is not approved for systemic therapy. It has been found in clinical studies to inhibit estrogen-induced proliferation of breast epithelial cells and to abolish breast pain and tenderness in women with the condition.
Historically, progesterone has been widely used in the treatment of premenstrual syndrome. A 2012 Cochrane review found insufficient evidence for or against the effectiveness of progesterone for this indication. Another review of 10 studies found that progesterone was not effective for this condition, although it stated that insufficient evidence is available currently to make a definitive statement on progesterone in premenstrual syndrome.
Progesterone is available in a variety of different forms, including oral capsules, sublingual tablets, vaginal capsules, tablets, gels, suppositories, and rings; rectal suppositories; oil solutions for intramuscular injection; and aqueous solutions for subcutaneous injection. A 1% topical progesterone gel is approved for local application to the breasts to treat breast pain, but is not indicated for systemic therapy. Progesterone was previously available as an intrauterine device for use in hormonal contraception, but this formulation was discontinued. Progesterone is also limitedly available in combination with estrogens such as estradiol and estradiol benzoate for use by intramuscular injection.
In addition to approved pharmaceutical products, progesterone is available in unregulated custom compounded and over-the-counter formulations like systemic transdermal creams and other preparations. The systemic efficacy of transdermal/topical progesterone is controversial and has not been demonstrated.
|Route||Form||Dose||Major brand names|
|Oral||Capsules||100, 200, 300 mg||Prometrium, Utrogestan, Microgest|
|Sublingual||Tablets||50, 100 mg||Luteina|
|Topicala||Gel||1% (25 mg)||Progestogel|
|Vaginal||Capsules||100, 200 mg||Utrogestan|
|Tablets||100 mg||Endometrin, Lutinus|
|Gel||4%, 8% (45, 90 mg)||Crinone, Crinone 8%, Prochieve|
|Suppositories||200, 400 mg||Cyclogest|
|Rings||10 mg/day for 3 months||Fertiring, Progering|
|Rectal||Suppositories||200, 400 mg||Cyclogest|
|Intramuscular injection||Vials||10, 25, 50, 100 mg/mL||Progestaject, Gestone, Strone|
|Subcutaneous injection||Vials||25 mg/vial||Prolutex|
|Footnotes: a = For application to the breasts; no systemic effect. Notes: (1): This table does not include combination products, such as progesterone in combination with estrogens. (2): Some of these formulations have been marketed previously but may no longer be available. (3): The availability of pharmaceutical progesterone products differs by country (see Progesterone (medication) § Availability). (4): This table does not include compounded progesterone products. Sources: See template.|
Contraindications of progesterone include hypersensitivity to progesterone or progestogens, prevention of cardiovascular disease (a Black Box warning), thrombophlebitis, thromboembolic disorder, cerebral hemorrhage, impaired liver function or disease, breast cancer, reproductive organ cancers, undiagnosed vaginal bleeding, missed menstruations, miscarriage, or a history of these conditions. Progesterone should be used with caution in people with conditions that may be adversely affected by fluid retention such as epilepsy, migraine headaches, asthma, cardiac dysfunction, and renal dysfunction. It should also be used with caution in patients with anemia, diabetes mellitus, a history of depression, previous ectopic pregnancy, venereal disease, and unresolved abnormal Pap smear. Use of progesterone is not recommended during pregnancy and breastfeeding. However, the medication has been deemed usually safe in breastfeeding by the American Academy of Pediatrics, but should not be used during the first four months of pregnancy. Some progesterone formulations contain benzyl alcohol, and this may cause a potentially fatal "gasping syndrome" if given to premature infants.
Progesterone is well-tolerated and many clinical studies have reported no side effects. Side effects of progesterone may include abdominal cramps, back pain, breast tenderness, constipation, nausea, dizziness, edema, vaginal bleeding, hypotension, fatigue, dysphoria, depression, and irritability. Side effects including drowsiness, sedation, sleepiness, fatigue, sluggishness, reduced vigor, dizziness, lightheadedness, decreased mental acuity, confusion, and cognitive, memory, and/or motor impairment may occur with oral ingestion and/or at high doses of progesterone, and are due to progesterone's neurosteroid metabolites (namely allopregnanolone). The same may be true for side effects of progesterone including dysphoria, depression, anxiety, and irritability, and both the adverse cognitive/sedative and emotional side effects of progesterone may be reduced or avoided by parenteral routes of administration such as vaginal or intramuscular injection. Also, progesterone may be taken before bed to avoid these side effects and/or to help with sleep.
Vaginal progesterone may be associated with vaginal irritation, itchiness, and discharge, decreased libido, painful sexual intercourse, vaginal bleeding or spotting in association with cramps, and local warmth or a "feeling of coolness" without discharge. Intramuscular injection may cause mild-to-moderate pain at the site of injection. High intramuscular doses of progesterone have been associated with increased body temperature, which may be alleviated with paracetamol treatment.
Unlike various progestins, progesterone lacks off-target hormonal side effects caused by, for instance, androgenic, antiandrogenic, glucocorticoid, or estrogenic activity. Conversely, it can still produce side effects related to its antimineralocorticoid and neurosteroid activity. The neurosteroid side effects of progesterone are notably not shared with progestins and hence are unique to progesterone. Compared to the progestin medroxyprogesterone acetate, there are fewer reports of breast tenderness with progesterone, and the magnitude and duration of vaginal bleeding with progesterone is reported to be lower.
The combination of an estrogen and progesterone has not been found to increase the risk of breast cancer in postmenopausal women. In contrast, all assessed progestins except the atypical progestin dydrogesterone have been associated with a significantly increased risk of breast cancer when used in combination with an estrogen in menopausal hormone therapy. On the other hand, progesterone is associated with a significantly increased risk of endometrial cancer in combination with an estrogen, while this is not true with any progestin. However, this does not appear to be the case with vaginal progesterone, which achieves high local concentrations of progesterone in the uterus that are likely fully sufficient for endometrial protection. Whereas the combination of an estrogen and a progestin is associated with an increased risk of venous thromboembolism relative to estrogen alone, there is no further increase in the risk of venous thromboembolism with the combination of an estrogen and oral progesterone relative to estrogen only. In addition, the combination of transdermal estradiol with oral progesterone is not associated with any increased risk of venous thromboembolism (RR = 0.93). The reasons for these differences between progesterone and progestins are not entirely clear, but may be due to the relatively low potency of oral progesterone and a potentially inadequate progestogenic effect of this medication.
Progesterone is likely to be relatively safe in overdose. Levels of progesterone during pregnancy are up to 100-fold higher than during normal menstrual cycling, although levels increase gradually over the course of pregnancy. Oral dosages of progesterone of as high as 3,600 mg/day have been assessed in clinical trials, with the main side effect being sedation. There is a case report of progesterone misuse with an oral dosage of 6,400 mg per day. Administration of as much as 1,000 mg progesterone by intramuscular injection in humans was uneventful in terms of toxicity, but did induce extreme sedation and somnolence accompanied by nearly unarousable sleep, though the individuals were still able to be awakened with sufficient physical stimulation.
There are several notable drug interactions with progesterone. Certain selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, and sertraline may increase the GABAA receptor-related central depressant effects of progesterone by enhancing its conversion into 5α-dihydroprogesterone and allopregnanolone via activation of 3α-HSD. Progesterone potentiates the sedative effects of benzodiazepines and alcohol. Notably, there is a case report of progesterone abuse alone with very high doses. 5α-Reductase inhibitors such as finasteride and dutasteride inhibit the conversion of progesterone into the inhibitory neurosteroid allopregnanolone, and for this reason, may have the potential to reduce the sedative and related effects of progesterone.
Progesterone is a weak but significant agonist of the pregnane X receptor (PXR), and has been found to induce several hepatic cytochrome P450 enzymes, such as CYP3A4, especially when concentrations are high, such as with pregnancy range levels. As such, progesterone may have the potential to accelerate the metabolism of various medications.
Progesterone is a progestogen, or an agonist of the nuclear progesterone receptors (PRs), the PR-A, PR-B, and PR-C. In addition, progesterone is an agonist of the membrane progesterone receptors (mPRs), including the mPRα, mPRβ, mPRγ, mPRδ, and mPRϵ. Aside from the PRs and mPRs, progesterone is a potent antimineralocorticoid, or antagonist of the mineralocorticoid receptor, the biological target of the mineralocorticoid aldosterone. In addition to its activity as a steroid hormone, progesterone is a neurosteroid. Among other neurosteroid activities, and via its active metabolites allopregnanolone and pregnanolone, progesterone is a potent positive allosteric modulator of the GABAA receptor, the major signaling receptor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).
The PRs are expressed widely throughout the body, including in the uterus, cervix, vagina, fallopian tubes, breasts, fat, skin, pituitary gland, hypothalamus, and in other areas of the brain. In accordance, progesterone has numerous effects throughout the body. Among other effects, progesterone produces changes in the female reproductive system, the breasts, and the brain. Progesterone has functional antiestrogenic effects due to its progestogenic activity, including in the uterus, cervix, and vagina. The effects of progesterone may influence health in both positive and negative ways. In addition to the aforementioned effects, progesterone has antigonadotropic effects due to its progestogenic activity, and can inhibit ovulation and suppress gonadal sex hormone production.
The activities of progesterone besides those mediated by the PRs and mPRs are also of significance. Progesterone lowers blood pressure and reduces water and salt retention among other effects via its antimineralocorticoid activity. In addition, progesterone can produce sedative, hypnotic, anxiolytic, euphoric, cognitive-, memory-, and motor-impairing, anticonvulsant, and even anesthetic effects via formation of sufficiently high concentrations of its neurosteroid metabolites and consequent GABAA receptor potentiation in the brain.
There are differences between progesterone and other progestogens, such as progestins like medroxyprogesterone acetate and norethisterone, with implications for pharmacodynamics and pharmacokinetics as well as efficacy, tolerability, and safety.
The pharmacokinetics of progesterone are dependent on its route of administration. The medications is approved in the form of oil-filled capsules containing micronized progesterone for oral administration, termed oral micronized progesterone or OMP. It is also available in the form of vaginal or rectal suppositories or pessaries, topical creams and gels, oil solutions for intramuscular injection, and aqueous solutions for subcutaneous injection.
Routes of administration that progesterone has been used by include oral, intranasal, transdermal/topical, vaginal, rectal, intramuscular, subcutaneous, and intravenous injection. Vaginal progesterone is available in the form of progesterone capsules, tablets or inserts, gels, suppositories or pessaries, and rings.
Progesterone is a naturally occurring pregnane steroid and is also known as pregn-4-ene-3,20-dione. It has a double bond (4-ene) between the C4 and C5 positions and two ketone groups (3,20-dione), one at the C3 position and the other at the C20 position. Due to its pregnane core and C4(5) double bond, progesterone is often abbreviated as P4. It is contrasted with pregnenolone, which has a C5(6) double bond and is often abbreviated as P5.
A large number of progestins, or synthetic progestogens, have been derived from progesterone. They can be categorized into several structural groups, including derivatives of retroprogesterone, 17α-hydroxyprogesterone, 17α-methylprogesterone, and 19-norprogesterone, with a respective example from each group including dydrogesterone, medroxyprogesterone acetate, medrogestone, and promegestone. The progesterone ethers quingestrone (progesterone 3-cyclopentyl enol ether) and progesterone 3-acetyl enol ether are among the only examples that do not belong to any of these groups. Another major group of progestins, the 19-nortestosterone derivatives, exemplified by norethisterone (norethindrone) and levonorgestrel, are not derived from progesterone but rather from testosterone.
A variety of synthetic inhibitory neurosteroids have been derived from progesterone and its neurosteroid metabolites, allopregnanolone and pregnanolone. Examples include alfadolone, alfaxolone, ganaxolone, hydroxydione, minaxolone, and renanolone. In addition, C3 and C20 conjugates of progesterone, such as progesterone carboxymethyloxime (progesterone 3-(O-carboxymethyl)oxime; P4-3-CMO), P1-185 (progesterone 3-O-(L-valine)-E-oxime), EIDD-1723 (progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt), EIDD-036 (progesterone 20-oxime; P4-20-O), and VOLT-02 (chemical structure unreleased), have been developed as water-soluble prodrugs of progesterone and neurosteroids.
The hormonal action of progesterone was discovered in 1929. Pure crystalline progesterone was isolated in 1934 and its chemical structure was determined. Later that year, chemical synthesis of progesterone was accomplished. Shortly following its chemical synthesis, progesterone began being tested clinically in women. In 1934, Schering introduced progesterone for use as a pharmaceutical drug by intramuscular injection under the brand name Proluton. A parenteral route was used because oral progesterone had very low activity and was originally thought to be inactive.
The first study of oral progesterone in humans was published in 1949. It found that oral progesterone produced significant progestational effects on the endometrium in women. Prior to this study, animal research had suggested that oral progesterone was inactive, and for this reason, oral progesterone had never been evaluated in humans. A variety of other early studies of oral progesterone in humans were also published in the 1950s and 1960s. These studies generally reported oral progesterone to be only very weakly active.
Progesterone was the first progestogen that was found to inhibit ovulation, both in animals and in women. Injections of progesterone were first shown to inhibit ovulation in between 1937 and 1939. Inhibition of fertilization by administration of progesterone during the luteal phase was also demonstrated in animals between 1947 and 1949. Ovulation inhibition by progesterone in animals was subsequently re-confirmed and expanded on by Gregory Pincus and colleagues in 1953 and 1954. Findings on inhibition of ovulation by progesterone in women were first presented at the Fifth International Conference on Planned Parenthood in Tokyo, Japan in October 1955. Three different research groups presented findings on ovulation inhibition by oral progesterone at this conference. They included Pincus (in conjunction with John Rock, who did not attend the conference); a nine-member Japanese group led by Masaomi Ishikawa; and the two-member team of Abraham Stone and Herbert Kupperman. The conference marked the beginning of a new era in the history of birth control. The findings of ovulation inhibition by oral progesterone were subsequently published in scientific journals in 1956 in the case of Pincus and in 1957 in the case of Ishikawa and colleagues. Rock and Pincus also subsequently described findings from 1952 that "pseudopregnancy" therapy with a combination of high doses of diethylstilbestrol and oral progesterone prevented ovulation and pregnancy in women.
Unfortunately, the use of oral progesterone as a hormonal contraceptive was plagued by problems. These included the large and by extension expensive doses required, incomplete inhibition of ovulation even at such high doses, and a frequent incidence of breakthrough bleeding. At the 1955 Tokyo conference, Pincus had also presented the first findings of ovulation inhibition by oral progestins in animals, specifically 19-nortestosterone derivatives like noretynodrel and norethisterone. These progestins were far more potent than progesterone, requiring much smaller doses orally. By December 1955, inhibition of ovulation by oral noretynodrel and norethisterone had been demonstrated in women. The findings of ovulation inhibition by the 19-nortestosterone progestins in animals and women were published in 1956. These progestins did not show the problems associated with oral progesterone; in the manners used in the studies, they fully inhibited ovulation and did not produce menstruation-related side effects. In relation to this, oral progesterone was abandoned as a hormonal contraceptive in women. The first birth control pills to be introduced were a noretynodrel-containing product in 1957 and a norethisterone-containing product in 1963, followed by numerous others containing a diversity of progestins. Progesterone itself has never been introduced for use in birth control pills.
More modern clinical studies of oral progesterone demonstrating elevated levels of progesterone and end-organ responses, specifically progestational endometrial changes, were published between 1980 and 1983. Up to this point, many clinicians and researchers still believed that oral progesterone was inactive. It was not until almost half a century after the introduction of progesterone in medicine that an oral formulation of progesterone was marketed. Micronization of progesterone and suspension in oil-filled capsules, which allowed progesterone to be absorbed several-fold more efficiently by the oral route, was first studied in the late 1970s and described in literature in 1982. This formulation, known as oral micronized progesterone (OMP), was then introduced for medical use under the brand name Utrogestan in France in 1982. Subsequently, oral micronized progesterone was introduced under the brand name Prometrium in the United States in 1998. By 1999, oral micronized progesterone had been marketed in more than 35 countries. In 2019, the first combination of oral estradiol and progesterone was introduced under the brand name Bijuva in the United States.
Other forms and routes
Vaginal progesterone suppositories were first studied in women by Robert Greenblatt in 1954. Shortly thereafter, vaginal progesterone suppositories were introduced for medical use under the brand name Colprosterone in 1955. Rectal progesterone suppositories were first studied in men and women by Christian Hamburger in 1965. Vaginal and rectal progesterone suppositories were introduced for use under the brand name Cyclogest by 1976. Vaginal micronized progesterone gels and capsules were introduced for medical use under brand names such as Utrogestan and Crinone in the early 1990s. Progesterone was approved in the United States as a vaginal gel in 1997 and as a vaginal insert in 2007. A progesterone contraceptive vaginal ring known as Progering was first studied in women in 1985 and continued to be researched through the 1990s. It was approved for use as a contraceptive in lactating mothers in Latin America by 2004. A second progesterone vaginal ring known as Fertiring was developed as a progesterone supplement for use during assisted reproduction and was approved in Latin America by 2007.
Development of a progesterone-containing intrauterine device (IUD) for contraception began in the 1960s. Incorporation of progesterone into IUDs was initially studied to help reduce the risk of IUD expulsion. However, while addition of progesterone to IUDs showed no benefit on expulsion rates, it was unexpectedly found by Antonio Scommegna to induce endometrial atrophy. This led to the development and introduction of Progestasert, a progesterone-containing product and the first progestogen-containing IUD, in 1976. Unfortunately, the product had various problems that limited its use. These included a short duration of efficacy of only one year, a high cost, a relatively high 2.9% failure rate, a lack of protection against ectopic pregnancy, and difficult and sometimes painful insertions that could necessitate use of a local anesthetic or analgesic. As a result of these issues, Progestasert never became widely used, and was discontinued in 2001. It was used mostly in the United States and France while it was marketed.
A topical gel formulation of progesterone for direct application to the breasts in local treatment of breast disorders such as mastodynia was introduced under the brand name Progestogel in Europe by 1972. No transdermal formulations of progesterone have been successfully marketed for systemic use, despite efforts of pharmaceutical companies towards this goal.
Sublingual progesterone in women was first studied in 1944 by Greenblatt. Buccal progesterone was first studied by Soule and Yanow in 1953. A sublingual tablet formulation of progesterone has been marketed under the brand name Luteina in Poland and Ukraine.
Subcutaneous pellet implants of progesterone were first studied in women in the late 1930s. They were reported to be extruded out of the skin within a few weeks at high rates and produced frequent inflammatory reactions at the site of implantation. Consequently, they were soon abandoned. However, subcutaneous pellet implants of progesterone were later studied as a form of birth control in women in the 1980s and early 1990s.
Society and culture
Progesterone is the generic name of the drug in English and its INN, USAN, USP, BAN, DCIT, and JAN, while progestérone is its name in French and its DCF. It is also referred to as progesteronum in Latin, progesterona in Spanish and Portuguese, and progesteron in German.
Progesterone is marketed under a large number of brand names throughout the world. Examples of major brand names under which progesterone has been marketed include Crinone, Crinone 8%, Cyclogest, Endogest, Endometrin, Estima, Geslutin, Gesterol, Gestone, Luteina, Luteinol, Lutigest, Lutinus, Microgest, Progeffik, Progelan, Progendo, Progering, Progest, Progestaject, Progestan, Progesterone, Progestin, Progestogel, Prolutex, Proluton, Prometrium, Prontogest, Strone, Susten, Utrogest, and Utrogestan.
Progesterone is widely available in countries throughout the world in a variety of formulations. Progesterone in the form of oral capsules; vaginal capsules, tablets/inserts, and gels; and intramuscular oil have widespread availability. The following formulations/routes of progesterone have selective or more limited availability:
- A tablet of micronized progesterone which is marketed under the brand name Luteina is indicated for sublingual administration in addition to vaginal administration and is available in Poland and Ukraine.
- A progesterone suppository which is marketed under the brand name Cyclogest is indicated for rectal administration in addition to vaginal administration and is available in Cyprus, Hong Kong, India, Malaysia, Malta, Oman, Singapore, South Africa, Thailand, Tunisia, Turkey, the United Kingdom, and Vietnam.
- An aqueous solution of progesterone complexed with β-cyclodextrin for subcutaneous injection is marketed under the brand name Prolutex in the Czech Republic, Hungary, Italy, Poland, Portugal, Slovakia, Spain, and Switzerland.
- A non-systemic topical gel formulation of progesterone for local application to the breasts to treat breast pain is marketed under the brand name Progestogel and is available in Belgium, Bulgaria, Colombia, Ecuador, France, Georgia, Germany, Hong Kong, Lebanon, Peru, Romania, Russia, Serbia, Switzerland, Tunisia, Venezuela, and Vietnam. It was also formerly available in Italy, Portugal, and Spain, but was discontinued in these countries.
- A progesterone intrauterine device was previously marketed under the brand name Progestasert and was available in Canada, France, the United States, and possibly other countries, but was discontinued.
- Progesterone vaginal rings are marketed under the brand names Fertiring and Progering and are available in Chile, Ecuador, and Peru.
- A combination pack of progesterone capsules for oral use and estradiol gel for transdermal use is marketed under the brand name Estrogel Propak in Canada.
- A combination pack of progesterone capsules and estradiol tablets for oral use is marketed in an under the brand name Duogestan in Belgium.
- Progesterone and estradiol in an aqueous suspension for use by intramuscular injection is marketed under the brand name Cristerona FP in Argentina.
- Progesterone and estradiol in microspheres in an oil solution for use by intramuscular injection is marketed under the brand name Juvenum in Mexico.
- Progesterone and estradiol benzoate in an oil solution for use by intramuscular injection is marketed under the brand names Duogynon, Duoton Fort T P, Emmenovis, Gestrygen, Lutofolone, Menovis, Mestrolar, Metrigen Fuerte, Nomestrol, Phenokinon-F, Prodiol, Pro-Estramon-S, Proger F, Progestediol, and Vermagest and is available in Belize, Egypt, El Salvador, Ethiopia, Guatemala, Honduras, Italy, Lebanon, Malaysia, Mexico, Nicaragua, Taiwan, Thailand, and Turkey.
- Progesterone and estradiol hemisuccinate in an oil solution for use by intramuscular injection is marketed under the brand name Hosterona in Argentina.
- Progesterone and estrone for use by intramuscular injection is marketed under the brand name Synergon in Monaco.
- Oral: Capsules: Prometrium (100 mg, 200 mg, 300 mg)
- Vaginal: Tablets: Endometrin (100 mg); Gels: Crinone (4%, 8%)
- Intramuscular injection: Oil: Progesterone (50 mg/mL)
A 25 mg/mL concentration of progesterone oil for intramuscular injection and a 38 mg/device progesterone intrauterine device (Progestasert) have been discontinued.
An oral combination formulation of micronized progesterone and estradiol in oil-filled capsules (developmental code name TX-001HR) is currently under development in the United States for the treatment of menopausal symptoms and endometrial hyperplasia, though it has yet to be approved or introduced.
Progesterone is also available in unregulated custom preparations from compounding pharmacies in the United States. In addition, transdermal progesterone is available over-the-counter in the United States, although the clinical efficacy of transdermal progesterone is controversial.
- Adler N, Pfaff D, Goy RW (6 December 2012). Handbook of Behavioral Neurobiology Volume 7 Reproduction (1st ed.). New York: Plenum Press. p. 189. ISBN 978-1-4684-4834-4. Retrieved 4 July 2015.
- Levine H, Watson N (March 2000). "Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3)". Fertil. Steril. 73 (3): 516–21. doi:10.1016/S0015-0282(99)00553-1. PMID 10689005.
- Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, van Amsterdam P, Pexman-Fieth C, Fauser BC (February 2019). "Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction". Reprod. Biomed. Online. 38 (2): 249–259. doi:10.1016/j.rbmo.2018.11.017. PMID 30595525.
- Pandya, Manish R; Gopeenathan, P.; Gopinath, P.M.; Das, S.K.; Sauhta, Meenakshi; Shinde, Veena (2016). "Evaluating the clinical efficacy and safety of progestogens in the management of threatened and recurrent miscarriage in early pregnancy-A review of the literature". Indian Journal of Obstetrics and Gynecology Research. 3 (2): 157. doi:10.5958/2394-2754.2016.00043.6. ISSN 2394-2746.
- Paulson RJ, Collins MG, Yankov VI (November 2014). "Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert". J. Clin. Endocrinol. Metab. 99 (11): 4241–9. doi:10.1210/jc.2013-3937. PMID 24606090.
- Fritz MA, Speroff L (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 44–. ISBN 978-1-4511-4847-3.
- Marshall WJ, Marshall WJ, Bangert SK (2008). Clinical Chemistry. Elsevier Health Sciences. pp. 192–. ISBN 978-0-7234-3455-9.
- Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (December 2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–16. doi:10.1097/GME.0000000000000467. PMC 4666011. PMID 25944519.
- Хомяк, Н. В., Мамчур, В. И., & Хомяк, Е. В. (2014). Клинико-фармакологические особенности современных лекарственных форм микронизированного прогестерона, применяющихся во время беременности. Здоровье, (4), 90. http://health-ua.com/wp-content/uploads/2015/09/MAZG2-2015_28-35.pdf
- Mircioiu C, Perju A, Griu E, Calin G, Neagu A, Enachescu D, Miron DS (1998). "Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration". Eur J Drug Metab Pharmacokinet. 23 (3): 397–402. doi:10.1007/BF03192300. PMID 9842983.
- Simon JA, Robinson DE, Andrews MC, Hildebrand JR, Rocci ML, Blake RE, Hodgen GD (1993). "The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone". Fertil. Steril. 60 (1): 26–33. doi:10.1016/S0015-0282(16)56031-2. PMID 8513955.
- Cometti B (November 2015). "Pharmaceutical and clinical development of a novel progesterone formulation". Acta Obstetricia et Gynecologica Scandinavica. 94 Suppl 161: 28–37. doi:10.1111/aogs.12765. PMID 26342177.
The administration of progesterone in injectable or vaginal form is more efficient than by the oral route, since it avoids the metabolic losses of progesterone encountered with oral administration resulting from the hepatic first-pass effect (32). In addition, the injectable forms avoid the need for higher doses that cause a fairly large number of side-effects, such as somnolence, sedation, anxiety, irritability and depression (33).
- Aufrère MB, Benson H (June 1976). "Progesterone: an overview and recent advances". J Pharm Sci. 65 (6): 783–800. doi:10.1002/jps.2600650602. PMID 945344.
- Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
- Wesp LM, Deutsch MB (2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". Psychiatr. Clin. North Am. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID 28159148.
- Ruan X, Mueck AO (November 2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–55. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.
- Filicori M (2015). "Clinical roles and applications of progesterone in reproductive medicine: an overview". Acta Obstet Gynecol Scand. 94 Suppl 161: 3–7. doi:10.1111/aogs.12791. PMID 26443945.
- Ciampaglia W, Cognigni GE (2015). "Clinical use of progesterone in infertility and assisted reproduction". Acta Obstet Gynecol Scand. 94 Suppl 161: 17–27. doi:10.1111/aogs.12770. PMID 26345161.
- Choi SJ (2017). "Use of progesterone supplement therapy for prevention of preterm birth: review of literatures". Obstet Gynecol Sci. 60 (5): 405–420. doi:10.5468/ogs.2017.60.5.405. PMC 5621069. PMID 28989916.
- Whitaker A, Gilliam M (2014). Contraception for Adolescent and Young Adult Women. Springer. p. 98. ISBN 9781461465799.
- Chaudhuri (2007). Practice Of Fertility Control: A Comprehensive Manual (7Th Edition). Elsevier India. pp. 153–. ISBN 978-81-312-1150-2.
- Goletiani NV, Keith DR, Gorsky SJ (2007). "Progesterone: review of safety for clinical studies". Exp Clin Psychopharmacol. 15 (5): 427–44. doi:10.1037/1064-12188.8.131.527. PMID 17924777.
- Stute P, Neulen J, Wildt L (2016). "The impact of micronized progesterone on the endometrium: a systematic review". Climacteric. 19 (4): 316–28. doi:10.1080/13697137.2016.1187123. PMID 27277331.
- Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29, 139. ISBN 978-1-4613-2157-6.CS1 maint: uses authors parameter (link)
- Coutinho EM, Segal SJ (1999). Is Menstruation Obsolete?. Oxford University Press. pp. 31–. ISBN 978-0-19-513021-8.
- Seaman B (4 January 2011). The Greatest Experiment Ever Performed on Women: Exploding the Estrogen Myth. Seven Stories Press. pp. 27–. ISBN 978-1-60980-062-8.
- Simon JA (December 1995). "Micronized progesterone: vaginal and oral uses". Clinical Obstetrics and Gynecology. 38 (4): 902–14. doi:10.1097/00003081-199538040-00024. PMID 8616985.
- Csech J, Gervais C (September 1982). "L'utrogestan" [Utrogestan]. Soins. Gynécologie, Obstétrique, Puériculture, Pédiatrie (in French) (16): 45–6. PMID 6925387.
- "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
- Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". Am J Clin Dermatol. 4 (6): 371–8. doi:10.2165/00128071-200304060-00001. PMID 12762829.
- Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB, Schmidt B (2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". Br. J. Dermatol. 153 (3): 626–34. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154.
- Schumacher M, Guennoun R, Ghoumari A, Massaad C, Robert F, El-Etr M, Akwa Y, Rajkowski K, Baulieu EE (June 2007). "Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system". Endocr. Rev. 28 (4): 387–439. doi:10.1210/er.2006-0050. PMID 17431228.
- Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, et al. (May 2008). "Progesterone receptors: form and function in brain". Front Neuroendocrinol. 29 (2): 313–39. doi:10.1016/j.yfrne.2008.02.001. PMC 2398769. PMID 18374402.
- Worsley R, Santoro N, Miller KK, Parish SJ, Davis SR (March 2016). "Hormones and Female Sexual Dysfunction: Beyond Estrogens and Androgens--Findings from the Fourth International Consultation on Sexual Medicine". J Sex Med. 13 (3): 283–90. doi:10.1016/j.jsxm.2015.12.014. PMID 26944460.
- World Professional Association for Transgender Health (September 2011), Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, Seventh Version (PDF), archived from the original (PDF) on 6 January 2016
- Ettner R, Monstrey S, Coleman E (20 May 2016). Principles of Transgender Medicine and Surgery. Routledge. pp. 170–. ISBN 978-1-317-51460-2.
- Wierckx K, Gooren L, T'Sjoen G (2014). "Clinical review: Breast development in trans women receiving cross-sex hormones". J Sex Med. 11 (5): 1240–7. doi:10.1111/jsm.12487. PMID 24618412.
- Copstead-Kirkhorn EC, Banasik JL (25 June 2014). Pathophysiology - E-Book. Elsevier Health Sciences. pp. 660–. ISBN 978-0-323-29317-4.
Throughout the reproductive years, some women note swelling of the breast around the latter part of each menstrual cycle before the onset of menstruation. The water retention and subsequent swelling of breast tissue during this phase of the menstrual cycle are thought to be due to high levels of circulating progesterone stimulating the secretory cells of the breast.12
- Farage MA, Neill S, MacLean AB (2009). "Physiological changes associated with the menstrual cycle: a review". Obstet Gynecol Surv. 64 (1): 58–72. doi:10.1097/OGX.0b013e3181932a37. PMID 19099613.
- da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M (February 2003). "Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study". American Journal of Obstetrics and Gynecology. 188 (2): 419–24. doi:10.1067/mob.2003.41. PMID 12592250.
- Harris, Gardiner (2 May 2011). "Hormone Is Said to Cut Risk of Premature Birth". New York Times. Retrieved 5 May 2011.
- O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. (October 2007). "Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial". Ultrasound in Obstetrics & Gynecology. 30 (5): 687–96. doi:10.1002/uog.5158. PMID 17899572.
- DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, Porter K, How H, Schakis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW (October 2007). "Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial". Ultrasound in Obstetrics & Gynecology. 30 (5): 697–705. doi:10.1002/uog.5159. PMID 17899571.
- Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH (August 2007). "Progesterone and the risk of preterm birth among women with a short cervix". The New England Journal of Medicine. 357 (5): 462–9. doi:10.1056/NEJMoa067815. PMID 17671254.
- Romero R (October 2007). "Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment". Ultrasound in Obstetrics & Gynecology. 30 (5): 675–86. doi:10.1002/uog.5174. PMID 17899585.
- Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. (July 2011). "Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial". Ultrasound in Obstetrics & Gynecology. 38 (1): 18–31. doi:10.1002/uog.9017. PMC 3482512. PMID 21472815. Lay summary – WebMD.
- "Progesterone helps cut risk of pre-term birth". Women's health. msnbc.com. 14 December 2011. Archived from the original on 15 December 2011. Retrieved 14 December 2011.
- Yanushpolsky EH (March 2015). "Luteal phase support in in vitro fertilization". Semin. Reprod. Med. 33 (2): 118–27. doi:10.1055/s-0035-1545363. PMID 25734349.
- Palomba S, Santagni S, La Sala GB (November 2015). "Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue?". J Ovarian Res. 8: 77. doi:10.1186/s13048-015-0205-8. PMC 4653859. PMID 26585269.
- Czyzyk A, Podfigurna A, Genazzani AR, Meczekalski B (June 2017). "The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility". Gynecol. Endocrinol. 33 (6): 421–424. doi:10.1080/09513590.2017.1291615. PMID 28277122.
- Falcone T, Hurd WW (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 406–. ISBN 978-0-323-03309-1.
- Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP (January 2012). "Evaluation and management of abnormal uterine bleeding in premenopausal women" (PDF). Am Fam Physician. 85 (1): 35–43. PMID 22230306.
- Hickey M, Higham JM, Fraser I (September 2012). "Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation". Cochrane Database Syst Rev (9): CD001895. doi:10.1002/14651858.CD001895.pub3. PMID 22972055.
- Wathen PI, Henderson MC, Witz CA (March 1995). "Abnormal uterine bleeding". Med. Clin. North Am. 79 (2): 329–44. doi:10.1016/S0025-7125(16)30071-2. PMID 7877394.
- Grossman D, White K, Harris L, Reeves M, Blumenthal PD, Winikoff B, Grimes DA (September 2015). "Continuing pregnancy after mifepristone and "reversal" of first-trimester medical abortion: a systematic review". Contraception. 92 (3): 206–11. doi:10.1016/j.contraception.2015.06.001. PMID 26057457.
- Ma, J; Huang, S; Qin, S; You, C; Zeng, Y (22 December 2016). "Progesterone for acute traumatic brain injury". The Cochrane Database of Systematic Reviews. 12: CD008409. doi:10.1002/14651858.CD008409.pub4. PMC 6463867. PMID 28005271.
- van Keep P, Utian W (6 December 2012). The Premenstrual Syndrome: Proceedings of a workshop held during the Sixth International Congress of Psychosomatic Obstetrics and Gynecology, Berlin, September 1980. Springer Science & Business Media. pp. 51–53. ISBN 978-94-011-6255-5.
- Bińkowska M, Woroń J (June 2015). "Progestogens in menopausal hormone therapy". Przeglad Menopauzalny = Menopause Review. 14 (2): 134–43. doi:10.5114/pm.2015.52154. PMC 4498031. PMID 26327902.
- Ruan X, Mueck AO (November 2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–55. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.
- Shaw RW, Luesley D, Monga AK (1 October 2010). Gynaecology E-Book: Expert Consult: Online and Print. Elsevier Health Sciences. pp. 417–. ISBN 978-0-7020-4838-8.
- Dickerson LM, Mazyck PJ, Hunter MH (2003). "Premenstrual syndrome". Am Fam Physician. 67 (8): 1743–52. PMID 12725453.
- Ford O, Lethaby A, Roberts H, Mol BW (2012). "Progesterone for premenstrual syndrome" (PDF). Cochrane Database Syst Rev (3): CD003415. doi:10.1002/14651858.CD003415.pub4. PMID 22419287.
- Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S (2001). "Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review". BMJ. 323 (7316): 776–80. doi:10.1136/bmj.323.7316.776. PMC 57352. PMID 11588078.
- Devinsky O, Schachter S, Pacia S (1 January 2005). Complementary and Alternative Therapies for Epilepsy. Demos Medical Publishing. pp. 378–. ISBN 978-1-934559-08-6.
- "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 29 November 2016.
- "Micromedex Products: Please Login".
- Kaunitz AM, Kaunitz JD (2015). "Compounded bioidentical hormone therapy: time for a reality check?". Menopause. 22 (9): 919–20. doi:10.1097/GME.0000000000000484. PMID 26035149.
- Pinkerton JV, Pickar JH (2016). "Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy". Menopause. 23 (2): 215–23. doi:10.1097/GME.0000000000000523. PMC 4927324. PMID 26418479.
- Stanczyk FZ (December 2014). "Treatment of postmenopausal women with topical progesterone creams and gels: are they effective?". Climacteric. 17 Suppl 2: 8–11. doi:10.3109/13697137.2014.944496. PMID 25196424.
- Stanczyk FZ, Paulson RJ, Roy S (2005). "Percutaneous administration of progesterone: blood levels and endometrial protection". Menopause. 12 (2): 232–7. doi:10.1097/00042192-200512020-00019. PMID 15772572.
- Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML, Bertino JS (2005). "Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product". J Clin Pharmacol. 45 (6): 614–9. doi:10.1177/0091270005276621. PMID 15901742.
- Aschenbrenner DS, Venable SJ (2009). Drug Therapy in Nursing. Lippincott Williams & Wilkins. pp. 1150–. ISBN 978-0-7817-6587-9.
- Moini J (29 October 2008). Fundamental Pharmacology for Pharmacy Technicians. Cengage Learning. pp. 322–. ISBN 978-1-111-80040-6.
- Wang-Cheng R, Neuner JM, Barnabei VM (2007). Menopause. ACP Press. p. 97. ISBN 978-1-930513-83-9.
- Bergemann N, Ariecher-Rössler A (27 December 2005). Estrogen Effects in Psychiatric Disorders. Springer Science & Business Media. p. 179. ISBN 978-3-211-27063-9.
- de Ziegler D, Fanchin R (2000). "Progesterone and progestins: applications in gynecology". Steroids. 65 (10–11): 671–9. doi:10.1016/s0039-128x(00)00123-9. PMID 11108875.
[...] fairly low plasma levels of progesterone have been reported when the hormone is given orally, and proper assays are used. Circulating levels of progesterone and its metabolites, determined by sufficiently specific assays, after oral and vaginal administration of 100 mg of progesterone are illustrated in Fig. 4. As can be seen, when taken orally, progesterone accounts for less than 10%, whereas most of ingested progesterone is transformed to 5α-reduced metabolites. The metabolites of progesterone that bind to the GABAA receptor complex are responsible for drowsiness and other neurologic side effects. [See also Figure 4 for bar graphs of metabolites.]
- Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D (February 2017). "Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis". Gynecol. Endocrinol. 33 (2): 87–92. doi:10.1080/09513590.2016.1248932. PMID 27898258.
- Lambrinoudaki I (2014). "Progestogens in postmenopausal hormone therapy and the risk of breast cancer". Maturitas. 77 (4): 311–7. doi:10.1016/j.maturitas.2014.01.001. PMID 24485796.
- Eden J (2017). "The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review". Aust N Z J Obstet Gynaecol. 57 (1): 12–15. doi:10.1111/ajo.12583. PMID 28251642.
- Kuhl H, Schneider HP (August 2013). "Progesterone--promoter or inhibitor of breast cancer". Climacteric. 16 Suppl 1: 54–68. doi:10.3109/13697137.2013.768806. PMID 23336704.
- Davey DA (March 2018). "Menopausal hormone therapy: a better and safer future". Climacteric. 21 (5): 454–461. doi:10.1080/13697137.2018.1439915. PMID 29526116.
- Scarabin PY (August 2018). "Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis". Climacteric. 21 (4): 341–345. doi:10.1080/13697137.2018.1446931. PMID 29570359.
- Plant TM, Zeleznik AJ (15 November 2014). Knobil and Neill's Physiology of Reproduction. Academic Press. pp. 2289, 2386. ISBN 978-0-12-397769-4.
- Schweizer E, Case WG, Garcia-Espana F, Greenblatt DJ, Rickels K (1995). "Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome". Psychopharmacology. 117 (4): 424–9. doi:10.1007/bf02246214. PMID 7604143.
- Keefe DL, Sarrel P (1996). "Dependency on progesterone in woman with self-diagnosed premenstrual syndrome". Lancet. 347 (9009): 1182. doi:10.1016/s0140-6736(96)90639-x. PMID 8609776.
- Merryman W, Boiman R, Barnes L, Rothchild I (1954). "Progesterone anesthesia in human subjects". J. Clin. Endocrinol. Metab. 14 (12): 1567–9. doi:10.1210/jcem-14-12-1567. PMID 13211793.
- Pinna G, Agis-Balboa RC, Pibiri F, Nelson M, Guidotti A, Costa E (October 2008). "Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice". Neurochemical Research. 33 (10): 1990–2007. doi:10.1007/s11064-008-9718-5. PMID 18473173.
- Babalonis S, Lile JA, Martin CA, Kelly TH (June 2011). "Physiological doses of progesterone potentiate the effects of triazolam in healthy, premenopausal women". Psychopharmacology. 215 (3): 429–39. doi:10.1007/s00213-011-2206-7. PMC 3137367. PMID 21350928.
- &Na (1996). "Progesterone abuse". Reactions Weekly. 599 (1): 9. doi:10.2165/00128415-199605990-00031. ISSN 1179-2051.
- Traish AM, Mulgaonkar A, Giordano N (June 2014). "The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression". Korean Journal of Urology. 55 (6): 367–79. doi:10.4111/kju.2014.55.6.367. PMC 4064044. PMID 24955220.
- Meyer L, Venard C, Schaeffer V, Patte-Mensah C, Mensah-Nyagan AG (April 2008). "The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury". Neurobiology of Disease. 30 (1): 30–41. doi:10.1016/j.nbd.2007.12.001. PMID 18291663.
- Pazol K, Wilson ME, Wallen K (June 2004). "Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques". The Journal of Clinical Endocrinology and Metabolism. 89 (6): 2998–3006. doi:10.1210/jc.2003-032086. PMC 1440328. PMID 15181090.
- Choi SY, Koh KH, Jeong H (February 2013). "Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone". Drug Metab. Dispos. 41 (2): 263–9. doi:10.1124/dmd.112.046276. PMC 3558868. PMID 22837389.
- Meanwell NA (8 December 2014). Tactics in Contemporary Drug Design. Springer. pp. 161–. ISBN 978-3-642-55041-6.
- Legato MJ, Bilezikian JP (2004). Principles of Gender-specific Medicine. Gulf Professional Publishing. pp. 146–. ISBN 978-0-12-440906-4.
- Lemke TL, Williams DA (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 164–. ISBN 978-1-60913-345-0.
- Soltysik K, Czekaj P (April 2013). "Membrane estrogen receptors - is it an alternative way of estrogen action?". J. Physiol. Pharmacol. 64 (2): 129–42. PMID 23756388.
- Prossnitz ER, Barton M (May 2014). "Estrogen biology: New insights into GPER function and clinical opportunities". Mol. Cell. Endocrinol. 389 (1–2): 71–83. doi:10.1016/j.mce.2014.02.002. PMC 4040308. PMID 24530924.
- Rupprecht R, Reul JM, van Steensel B, Spengler D, Söder M, Berning B, et al. (October 1993). "Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands". European Journal of Pharmacology. 247 (2): 145–54. doi:10.1016/0922-4106(93)90072-H. PMID 8282004.
- Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A (2003). "Conception and pharmacodynamic profile of drospirenone". Steroids. 68 (10–13): 891–905. doi:10.1016/j.steroids.2003.08.008. PMID 14667981.
- Baulieu E, Schumacher M (2000). "Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination". Steroids. 65 (10–11): 605–12. doi:10.1016/s0039-128x(00)00173-2. PMID 11108866.
- Paul SM, Purdy RH (March 1992). "Neuroactive steroids". FASEB Journal. 6 (6): 2311–22. doi:10.1096/fasebj.6.6.1347506. PMID 1347506.
- Bentley PJ (1980). Endocrine Pharmacology: Physiological Basis and Therapeutic Applications. CUP Archive. pp. 264, 274. ISBN 978-0-521-22673-8.
- Oelkers W (2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". Eur J Contracept Reprod Health Care. 5 Suppl 3: 17–24. PMID 11246598.
- Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G (2014). "Allopregnanolone and mood disorders". Prog. Neurobiol. 113: 88–94. doi:10.1016/j.pneurobio.2013.07.005. PMID 23978486.
- Zutshi (2005). Hormones in Obstetrics and Gynaecology. Jaypee Brothers, Medical Publishers. pp. 74–75. ISBN 978-81-8061-427-9.
It has been observed that micronized progesterone has no suppressive effects on high-density lipoprotein-cholesterol (HDL-C). Jensen et al have proved that oral micronized progesterone has no adverse effect on serum lipids. These preparations have the same antiestrogenic and antimineralocorticoid effect but no androgenic action. It does not affect aldosterone synthesis, blood pressure, carbohydrate metabolism or mood changes. No side effects have been reported as far as lipid profile, coagulation factors and blood pressure are concerned.
- Lark S (1999). Making the Estrogen Decision. McGraw-Hill Professional. p. 22. ISBN 9780879836962.
- Progesterone - Drugs.com, retrieved 23 August 2015
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1024–. ISBN 978-1-4757-2085-3.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 880–. ISBN 978-3-88763-075-1.
- Pincus G, Miyake T, Merrill AP, Longo P (November 1957). "The bioassay of progesterone". Endocrinology. 61 (5): 528–33. doi:10.1210/endo-61-5-528. PMID 13480263.
- Basu, Krishnakali; Mitra, Ashim K. (1990). "Effects of 3-hydrazone modification on the metabolism and protein binding of progesterone". International Journal of Pharmaceutics. 65 (1–2): 109–114. doi:10.1016/0378-5173(90)90015-V. ISSN 0378-5173.
- Wali B, Sayeed I, Guthrie DB, Natchus MG, Turan N, Liotta DC, Stein DG (October 2016). "Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats". Neuropharmacology. 109: 148–158. doi:10.1016/j.neuropharm.2016.05.017. PMID 27267687.
- Guthrie, D. B., Lockwood, M. A., Natchus, M. G., Liotta, D. C., Stein, D. G., & Sayeed, I. (2017). U.S. Patent No. 9,802,978. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US9802978B2/en
- MacNevin CJ, Atif F, Sayeed I, Stein DG, Liotta DC (October 2009). "Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury". J. Med. Chem. 52 (19): 6012–23. doi:10.1021/jm900712n. PMID 19791804.
- Guthrie DB, Stein DG, Liotta DC, Lockwood MA, Sayeed I, Atif F, et al. (May 2012). "Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury". ACS Med Chem Lett. 3 (5): 362–6. doi:10.1021/ml200303r. PMC 4025794. PMID 24900479.
- "Progesterone conjugate - Levolta Pharmaceuticals - AdisInsight".
- Die Gestagene. Springer-Verlag. 27 November 2013. pp. 5–. ISBN 978-3-642-99941-3.
- Walker A (7 March 2008). The Menstrual Cycle. Routledge. pp. 49–. ISBN 978-1-134-71411-7.
- Ginsburg B (6 December 2012). Premenstrual Syndrome: Ethical and Legal Implications in a Biomedical Perspective. Springer Science & Business Media. pp. 274–. ISBN 978-1-4684-5275-4.
- Gerald, Michael (2013). The Drug Book. New York, New York: Sterling Publishing. p. 186. ISBN 9781402782640.
- Bickers W (August 1949). "Progesterone; a comparison of intramuscular, oral and sublingual routes of administration". J. Clin. Endocrinol. Metab. 9 (8): 736–42. doi:10.1210/jcem-9-8-736. PMID 18133494.
- Greenblatt RB, Barfield WE, Clark S, Brown N (August 1950). "Physiologic effectiveness of oral progesterone". J. Clin. Endocrinol. Metab. 10 (8): 886–96. doi:10.1210/jcem-10-8-886. PMID 15436649.
- Bickers W (July 1952). "Menstrual arrhythmias; oral estrogen and progesterone therapy". Am. J. Obstet. Gynecol. 64 (1): 148–54. doi:10.1016/s0002-9378(16)38745-2. PMID 14933526.
- Mulligan WJ, Horne HW, Rock J (1952). "Cyclic oral therapy of menstrual disorders". Fertil. Steril. 3 (4): 328–33. doi:10.1016/S0015-0282(16)30965-7. PMID 12980155.
- Fischer RH, McColgan SP (September 1953). "Progesterone metabolism. II. Pregnanediol excretion following oral, sublingual and parenteral administration of progesterone". J. Clin. Endocrinol. Metab. 13 (9): 1043–53. doi:10.1210/jcem-13-9-1043. PMID 13084722.
- Frank R, Guterman HS (1954). "Comparison of progesterone preparations in secondary amenorrhea". Fertil. Steril. 5 (4): 374–81. doi:10.1016/S0015-0282(16)31687-9. PMID 13183192.
- Kupperman HS, Lefkovics SC (1957). "Progesterone in problems of sterility; diagnostic and therapeutic use". Fertil. Steril. 8 (2): 131–46, discussion, 146–8. doi:10.1016/S0015-0282(16)32642-5. PMID 13405054.
- Rock J, Garcia CR, Pincus G (1957). "Synthetic progestins in the normal human menstrual cycle". Recent Prog. Horm. Res. 13: 323–39, discussion 339–46. PMID 13477811.
- Birnberg CH, Livingston S, Davis JG (January 1958). "Large-dose oral progesterone therapy in menstrual disorders". Obstet Gynecol. 11 (1): 115–8. PMID 13504644.
- Volk, Herbert; Escher, George C.; Huseby, Robert A.; Tyler, Frank H.; Cheda, Jesus (1960). "Hormonal therapy in carcinoma of the breast.I. Effect of oral progesterone on clinical course and metabolism of nitrogen and selected electrolytes and steroids". Cancer. 13 (4): 757–763. doi:10.1002/1097-0142(196007/08)13:4<757::AID-CNCR2820130417>3.0.CO;2-9. ISSN 0008-543X.
- Aiko Takeuchi-Demirci (9 January 2018). Contraceptive Diplomacy: Reproductive Politics and Imperial Ambitions in the United States and Japan. Stanford University Press. pp. 188–191, 243. ISBN 978-1-5036-0441-4.
- Pincus G, Bialy G (1964). "Drugs Used in Control of Reproduction". Adv Pharmacol. Advances in Pharmacology. 3: 285–313. doi:10.1016/S1054-3589(08)61115-1. ISBN 9780120329038. PMID 14232795.
The original observation of Makepeace et al. (1937) that progesterone inhibited ovulation in the rabbit was substantiated by Pincus and Chang (1953). In women, 300 mg of progesterone per day taken orally resulted in ovulation inhibition in 80% of cases (Pincus, 1956). The high dosage and frequent incidence of breakthrough bleeding limited the practical application of the method. Subsequently, the utilization of potent 19-norsteroids, which could be given orally, opened the field to practical oral contraception.
- Chang MC (September 1978). "Development of the oral contraceptives". Am. J. Obstet. Gynecol. 132 (2): 217–9. doi:10.1016/0002-9378(78)90928-6. PMID 356615.
- Makepeace, A. W.; Weinstein, George Louis; Friedman, Maurice H. (1937). "The effect of progestin and progesterone on ovulation in the rabbit". American Journal of Physiology. Legacy Content. 119 (3): 512–516. doi:10.1152/ajplegacy.19184.108.40.2062. ISSN 0002-9513.
- Astwood, E. B.; Fevold, H. L. (1939). "Action of progesterone on the gonadotropic activity of the pituitary". American Journal of Physiology. Legacy Content. 127 (1): 192–198. doi:10.1152/ajplegacy.19220.127.116.11. ISSN 0002-9513.
- Pincus G, Chang MC (1953). "The effects of progesterone and related compounds on ovulation and early development in the rabbit". Acta Physiol Lat Am. 3 (2–3): 177–83. PMID 13138262.
- Slechta RF, Chang MC, Pincus G (1954). "Effects of progesterone and related compounds on mating and pregnancy in the rat". Fertil. Steril. 5 (3): 282–93. doi:10.1016/S0015-0282(16)31628-4. PMID 13162007.
- Diczfalusy E (December 1965). "Probable mode of action of oral contraceptives". Br Med J. 2 (5475): 1394–9. doi:10.1136/bmj.2.5475.1394. PMC 1847181. PMID 5848673.
At the Fifth International Conference on Planned Parenthood in Tokyo, Pincus (1955) reported an ovulation inhibition by progesterone or norethynodrel1 taken orally by women. This report indicated the beginning of a new era in the history of contraception. [...] That the cervical mucus might be one of the principal sites of action was suggested by the first studies of Pincus (1956, 1959) and of Ishikawa et al. (1957). These investigators found that no pregnancies occurred in women treated orally with large doses of progesterone, though ovulation was inhibited only in some 70% of the cases studied. [...] The mechanism of protection in this method—and probably in that of Pincus (1956) and of Ishikawa et al. (1957)—must involve an effect on the cervical mucus and/or endometrium and Fallopian tubes.
- Pincus, Gregory (1955). "Some Effects of Progesterone and Related Compounds upon Reproduction and Early Development in Mammals". The Fifth International Conference on Planned Parenthood: Theme, Overpopulation and Family Planning: Report of the Proceedings, 24-29 October, 1955, Tokyo, Japan. International Planned Parenthood Federation. pp. 175–184.
- Stone, Abraham; Kupperman, Herbert S. (1955). "The Effects of Progesterone on Ovulation: A Preliminary Report". The Fifth International Conference on Planned Parenthood: Theme, Overpopulation and Family Planning: Report of the Proceedings, 24-29 October, 1955, Tokyo, Japan. International Planned Parenthood Federation. p. 185.
The results of testing the effects of progesterone on ovulation in 13 patients at the Margaret Sanger Research Bureau are presented. The patients had normal menstrual cycles and showed clear evidence of ovulation. Each patient was given 1000 [mg] of [oral] progesterone daily during the midperiod for 10 or 12 days during 16 cycles. Ovulation was inhibited in 6 cycles. No disturbance in menstrual rhythm was observed. 3 of 12 patients with longstanding infertility histories became pregnant within 2-4 months after the cessation of progesterone therapy.
- Ishikawa, Masaomi; Kyushiro, Fujii; Yoshio, Furusawa; Takashi, Kobayashi; Masanao, Magara; Michio, Matsuba; Seiichi, Matsumoto; Tatsuo, Takashima; Sigeki, Takeuchi (1955). "Some Effects of Progesterone and Related Compounds upon Reproduction and Early Development in Mammals". The Fifth International Conference on Planned Parenthood: Theme, Overpopulation and Family Planning: Report of the Proceedings, 24-29 October, 1955, Tokyo, Japan. International Planned Parenthood Federation. pp. 186–187.
- Pincus G (1956). "Some effects of progesterone and related compounds upon reproduction and early development in mammals". Acta Endocrinol Suppl (Copenh). 23 (Suppl 28): 18–36. doi:10.1530/acta.0.023S018. PMID 13394044.
- Ishikawa M, Fujii K, Furusawa Y, Kobayashi T, Makino T, Matsumoto S, Takashima T, Takeuchi S. J. Jap. Family Plann. Ass. 2: 51–56. Missing or empty
- Pincus, Gregory (1959). Progestational Agents and the Control of Fertility. Vitamins & Hormones. 17. pp. 307–324. doi:10.1016/S0083-6729(08)60274-5. ISBN 9780127098173. ISSN 0083-6729.
Ishikawa et al. (1957) employing the same regime of progesterone administration also observed suppression of ovulation in a proportion of the cases taken to laparotomy. Although sexual intercourse was practised freely by the subjects of our experiments and those of Ishikawa el al., no pregnancies occurred. Since ovulation presumably took place in a proportion of cycles, the lack of any pregnancies may be due to chance, but Ishikawa et al. (1957) have presented data indicating that in women receiving oral progesterone the cervical mucus becomes impenetrable to sperm.
- Perone N (1993). "The history of steroidal contraceptive development: the progestins". Perspect. Biol. Med. 36 (3): 347–62. doi:10.1353/pbm.1993.0054. PMID 8506121.
- Dhont M (December 2010). "History of oral contraception". Eur J Contracept Reprod Health Care. 15 Suppl 2: S12–8. doi:10.3109/13625187.2010.513071. PMID 21091163.
- Annette B. Ramírez de Arellano; Conrad Seipp (10 October 2017). Colonialism, Catholicism, and Contraception: A History of Birth Control in Puerto Rico. University of North Carolina Press. pp. 106–112. ISBN 978-1-4696-4001-3.
[...] Still, neither of the two researchers was completely satisfied with the results. Progesterone tended to cause "premature menses," or breakthrough bleeding, in approximately 20 percent of the cycles, an occurrence that disturbed the patients and worried Rock.17 In addition, Pincus was concerned about the failure to inhibit ovulation in all the cases. Only large doses of orally administered progesterone could insure the suppression of ovulation, and these doses were expensive. The mass use of this regimen as a birth control method was thus seriously imperiled.18 [...]
- Margaret Marsh; Wanda Ronner (31 October 2008). The Fertility Doctor: John Rock and the Reproductive Revolution. JHU Press. pp. 333–. ISBN 978-1-4214-0208-6.
43. The first study used progesterone continuously rather than cyclically. Women began by taking 5 mg of stilbestrol and 50 mg of progesterone, increasing the dose of stilbestrol by 5 mg and of progesterone by 50 mg every two weeks. By the end of twelve weeks, women were taking 30 mg stilbestrol and 300 mg of progesterone. If they had vaginal bleeding at any time, the doses were increased. "Pseudopregnancy," typescript, July 15, 1954, GP-LC. Rock also summarizes his early studies in John Rock, Celso-Ramon Garcia, and Gregory Pincus, "Synthetic Progestins in the Normal Human Menstrual Cycle," Recent Progress in Hormone Research, vol. 13 (New York: Academic Press, 1957), 323-24.
- Elizabeth Siegel Watkins (14 September 2001). On the Pill: A Social History of Oral Contraceptives, 1950-1970. Johns Hopkins University Press. ISBN 978-1-4214-0371-7.
In the early 1950s, independent of Pincus's work in Worcester, Rock successfully induced pregnancy in previously infertile women by treating them for several months with estrogen and progesterone. Although the steroids prevented pregnancy during the course of therapy, some of the women conceived when the treatment ended; this phenomenon became known as the "Rock rebound effect."58 When Pincus learned of Rock's work, he asked the physician to join forces in the hunt for an ovulation inhibitor, and Rock agreed. Pincus suggested two changes in the experimental regimen: use only progesterone (estrogen promoted cancer in laboratory animals) and administer the hormone for twenty days each month (to allow a period of menstruation). Rock achieved the same rate of success in curing infertility (about 15%), but a significant problem remained: tests indicated that about 15 percent of the women ovulated while taking the progesterone.59 Pincus and Rock needed to find an orally active compound that would completely inhibit ovulation. It was time to test the 19-nor steroids in humans. [...]
- Pincus G, Change MC, Hafez ES, Zarrow MX, Merrill A (November 1956). "Effects of certain 19-nor steroids on reproductive processes in animals". Science. 124 (3227): 890–1. doi:10.1126/science.124.3227.890-a. PMID 13380400.
- Garcia CR, Pincus G, Rock J (November 1956). "Effects of certain 19-nor steroids on the normal human menstrual cycle". Science. 124 (3227): 891–3. doi:10.1126/science.124.3227.891. PMID 13380401.
- Lara Marks (2010). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 75–. ISBN 978-0-300-16791-7.
- Christin-Maitre S (February 2013). "History of oral contraceptive drugs and their use worldwide". Best Pract. Res. Clin. Endocrinol. Metab. 27 (1): 3–12. doi:10.1016/j.beem.2012.11.004. PMID 23384741.
- Whitehead MI, Townsend PT, Gill DK, Collins WP, Campbell S (March 1980). "Absorption and metabolism of oral progesterone". Br Med J. 280 (6217): 825–7. doi:10.1136/bmj.280.6217.825. PMC 1600943. PMID 7370683.
- Whitehead M, Lane G, Townsend P, Siddle N, Pryse-Davies J, King RJ (May 1981). "Oral progesterone". Br Med J (Clin Res Ed). 282 (6274): 1476. doi:10.1136/bmj.282.6274.1476-a. PMC 1505208. PMID 6784875.
- Morville R, Dray F, Reynier J, Barrat J (1982). "Biodisponibilité de la progestérone naturelle administrée par voie orale. Mesure des concentrations du stéroïde dans le plasma, l'endomètre et le tissu mammaire" [The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue]. J Gynecol Obstet Biol Reprod (Paris) (in French). 11 (3): 355–63. PMID 7119381.
- Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI (October 1983). "Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium". Br Med J (Clin Res Ed). 287 (6401): 1241–5. doi:10.1136/bmj.287.6401.1241. PMC 1549751. PMID 6315123.
- Adlercreutz H, Martin F (February 1980). "Biliary excretion and intestinal metabolism of progesterone and estrogens in man". J. Steroid Biochem. 13 (2): 231–44. doi:10.1016/0022-4731(80)90196-X. PMID 6991820.
It is generally accepted that orally administered progesterone has little biological effect.
- González ER (April 1981). "Even oral progesterone may be effective". JAMA. 245 (14): 1394. doi:10.1001/jama.1981.03310390003001. PMID 7193749.
- Sauer MV (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7.
- Piette P (August 2018). "The history of natural progesterone, the never-ending story". Climacteric. 21 (4): 308–314. doi:10.1080/13697137.2018.1462792. PMID 29806794.
- Hargrove JT, Maxson WS, Wentz AC (October 1989). "Absorption of oral progesterone is influenced by vehicle and particle size". Am. J. Obstet. Gynecol. 161 (4): 948–51. doi:10.1016/0002-9378(89)90759-X. PMID 2801843.
- de Lignières B (January 1999). "Oral micronized progesterone". Clin Ther. 21 (1): 41–60, discussion 1–2. doi:10.1016/S0149-2918(00)88267-3. PMID 10090424.
- "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: 019781". Food and Drug Administration. 2 July 2010. Retrieved 7 July 2010.
- "TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause".
- Greenblatt RB (December 1954). "The physiologic effectiveness of progesterone vaginal suppositories". J. Clin. Endocrinol. Metab. 14 (12): 1564–7. doi:10.1210/jcem-14-12-1564. PMID 13211792.
- Greenblatt RB, Clark SL (March 1957). "The use of newer progestational preparations in clinical practice". Med. Clin. North Am. 41 (2): 587–603. doi:10.1016/S0025-7125(16)34457-1. PMID 13407238.
- Benziger DP, Edelson J (1983). "Absorption from the vagina". Drug Metab. Rev. 14 (2): 137–68. doi:10.3109/03602538308991387. PMID 6301793.
- "NEW Prescription Products". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 16 (3): 193–200. 1955. doi:10.1016/S0095-9561(16)33664-7. ISSN 0095-9561.
- Hamburger, Christian (1965). "Administration of Progesterone in the Form of Suppositories". Acta Endocrinologica. 49 (3_Suppl): S101. doi:10.1530/acta.0.049S101. ISSN 0804-4643.
- Unlisted Drugs. Unlisted Drugs. 1976. p. 360.
- The Belfast Gazette. H.M. Stationery Office. January 1977. p. 158.
- Martin Negwer (1978). Organic-chemical Drugs and Their Synonyms. Akademie-Verlag. p. 872.
- Racowsky C, Schlegel PN, Fauser BC, Carrell D (7 June 2011). Biennial Review of Infertility. Springer Science & Business Media. pp. 84–85. ISBN 978-1-4419-8456-2.
- "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: 020701". Food and Drug Administration. 2 July 2010. Retrieved 7 July 2010.
- "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: 022057". Food and Drug Administration. 2 July 2010. Retrieved 7 July 2010.
- Faundes, Anibal; Brache, Vivian; Alvarez, Frank (2004). "Pros and Cons of Vaginal Rings for Contraceptive Hormone Delivery". American Journal of Drug Delivery. 2 (4): 241–250. doi:10.2165/00137696-200402040-00004. ISSN 1175-9038.
- Friend DR (October 2016). "Development of controlled release systems over the past 50years in the area of contraception". J Control Release. 240: 235–241. doi:10.1016/j.jconrel.2015.12.043. PMID 26732558.
- Rabe, T (2007). "Contraception – Update and Trends" (PDF). J. Reproduktionsmed. Endokrinol. 4 (6): 337–357. ISSN 1810-2107.
- Anya M Hillery; Kinam Park (15 September 2016). Drug Delivery: Fundamentals and Applications, Second Edition. CRC Press. pp. 294–. ISBN 978-1-4822-1772-8.
- Rose S, Chaudhari A, Peterson CM (August 2009). "Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception". Adv. Drug Deliv. Rev. 61 (10): 808–12. doi:10.1016/j.addr.2009.04.022. PMID 19445984.
- Journal de gynécologie, obstétrique et biologie de la reproduction. Masson. 1972. pp. 198, 214, 327.
- Sitruk-Ware R (January 1989). "Transdermal delivery of steroids". Contraception. 39 (1): 1–20. doi:10.1016/0010-7824(89)90012-7. PMID 2642780.
- Greenblatt, Robert B. (1944). "Sublingual Absorption of Progesterone and Anhydrohydroxyprogesterone". The Journal of Clinical Endocrinology & Metabolism. 4 (4): 156–158. doi:10.1210/jcem-4-4-156. ISSN 0021-972X.
- Greenblatt, Robert B. (1944). "Perlingual Absorption of Progesterone and Anhydrohydroxyprogesterone1,2". The Journal of Clinical Endocrinology & Metabolism. 4 (7): 321–325. doi:10.1210/jcem-4-7-321. ISSN 0021-972X.
- Soule SD, Yanow M (July 1953). "Recovery of pregnanediol from urine following administration of oral anhydrohydroxyprogesterone, buccal progesterone, and intramuscular progesterone". Obstet Gynecol. 2 (1): 68–72. PMID 13073082.
- Mishell, Daniel R. (1941). "A clinical study of progesterone therapy by pellet implantation". American Journal of Obstetrics and Gynecology. 41 (4): 687–693. doi:10.1016/S0002-9378(41)90665-8. ISSN 0002-9378.
- Foss, G.L. (1943). "Implantation of Sex Hormone Tablets in Man". British Medical Bulletin. 1 (2): 21–22. doi:10.1093/oxfordjournals.bmb.a070135. ISSN 1471-8391.
- Greenblatt, Robert B.; Hair, L. Quinby (1945). "Absorption of Pellets of Progesterone". The Journal of Clinical Endocrinology & Metabolism. 5 (1): 38–39. doi:10.1210/jcem-5-1-38. ISSN 0021-972X.
- Greenblatt RB, Suran RR (February 1949). "Indications for hormonal pellets in the therapy of endocrine and gynecic disorders". Am. J. Obstet. Gynecol. 57 (2): 294–301. doi:10.1016/0002-9378(49)90429-9. PMID 18123090.
- Bishop PM, Folley SJ (August 1951). "Absorption of hormone implants in man". Lancet. 2 (6676): 229–32. doi:10.1016/S0140-6736(51)93237-0. PMID 14862159.
- Bishop, P. M. F. (1944). "Endocrine Therapy in Gynaecology and Obstetrics". BJOG: An International Journal of Obstetrics and Gynaecology. 51 (1): 51–63. doi:10.1111/j.1471-0528.1944.tb07317.x. ISSN 1470-0328.
- Croxatto HB, Díaz S (1987). "The place of progesterone in human contraception". J. Steroid Biochem. 27 (4–6): 991–4. doi:10.1016/0022-4731(87)90179-8. PMID 3320572.
- Shaaban MM (1991). "Contraception with progestogens and progesterone during lactation". J. Steroid Biochem. Mol. Biol. 40 (4–6): 705–10. doi:10.1016/0960-0760(91)90294-F. PMID 1835650.
- Croxatto HB, Díaz S, Peralta O, Juez G, Casado ME, Salvatierra AM, Durán E (September 1982). "Fertility regulation in nursing women. II. Comparative performance of progesterone implants versus placebo and copper T". Am. J. Obstet. Gynecol. 144 (2): 201–8. doi:10.1016/0002-9378(82)90628-7. PMID 7114130.
- Díaz S, Peralta O, Juez G, Herreros C, Casado ME, Salvatierra AM, Miranda P, Croxatto HB (October 1984). "Fertility regulation in nursing women. VI. Contraceptive effectiveness of a subdermal progesterone implant". Contraception. 30 (4): 311–25. doi:10.1016/S0010-7824(84)80023-2. PMID 6509984.
- "Progesterone - IBSA - AdisInsight".
- Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 232–. ISBN 978-0-7514-0499-9.
- Gelijns A (1991). Innovation in Clinical Practice: The Dynamics of Medical Technology Development. National Academies. pp. 195–. NAP:13513.
- "Estradiol/progesterone injection - Laboratorios Carnot - AdisInsight".
- "Estradiol/progesterone - TherapeuticsMD - AdisInsight".